z-logo
open-access-imgOpen Access
The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism
Author(s) -
Jonathan Matalonga,
Estibaliz Glaría,
Mariana Bresque,
Carlos Escande,
Josep Maria Casasa i Carbo,
Kerstin Kiefer,
Rubén Vicente,
Theresa E. León,
Susana Beceiro,
Mónica Pascual-García,
Joan Serret,
Lucía Sanjurjo,
Samantha MorónRos,
Antoni Riéra,
Sònia Paytubi,
Antonio Juárez,
Fernando Sotillo,
Lennart Lindbom,
Carmé Caelles,
MariaRosa Sarrias,
Jaime Sancho,
Antonio Castrillo,
Eduardo N. Chini,
Annabel F. Valledor
Publication year - 2017
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2017.01.007
Subject(s) - biology , microbiology and biotechnology , nad+ kinase , effector , macrophage , liver x receptor , cd38 , intracellular , nuclear receptor , enzyme , biochemistry , in vitro , transcription factor , stem cell , gene , cd34
Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD + in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of non-opsonized Salmonella to infect macrophages. Remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bone-marrow-derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom